TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
ANRO

Alto Neuroscience, Inc.

Healthcare · Biotechnology

31.00$ +3.3% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Alto Neuroscience, Inc. (ANRO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 75.6% of the shares are freely tradable; institutional investors hold 82.1%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 82.1%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 4.6%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 75.6%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 11.5%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 39Mio.

Largest Shareholders

Institutions

Institutions ANRO
Name Stake (%) Shares Change (%) Date
Alpha Wave Global LP 9.45 3,707,757 +0.0 03/31/2026
COMMODORE CAPITAL LP 6.94 2,723,196 +49.4 03/31/2026
Vestal Point Capital LP 5.26 2,064,075 -16.9 03/31/2026
Perceptive Advisors LLC 4.10 1,609,893 -19.9 06/30/2026
Adage Capital Partners Gp LLC 4.08 1,600,000 +315.6 06/30/2026
Spruce Street Capital LP 3.45 1,353,047 +2.1 06/30/2026
Vivo Capital, LLC 3.08 1,208,858 +16.7 06/30/2026
Vanguard Capital Management, LLC 3.08 1,207,025 +0.0 03/31/2026
Franklin Templeton Inc 2.81 1,101,874 -1.6 03/31/2026

Funds

Funds ANRO
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.58 1,011,881 +0.0 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?